Breaking News

AGC Biologics, Asahi Kasei Enter Clinical Drug Substance Agreement

AGC to perform process transfer, process optimization, and clinical manufacturing at Seattle manufacturing site.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AGC Biologics, a global biopharmaceutical CDMO, entered a new agreement with Asahi Kasei Pharma to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.   AGC Biologics will leverage its monoclonal antibody development and manufacturing experience to perform process transfer, process optimization, and clinical manufacturing of the Asahi Kasei Pharma drug substance.   During this clinical phase, scientists at the Seattle manufacturing site ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters